Medicine
Cure8 research brief
Why This Matters
People with ulcerative colitis considering or taking ozanimod or etrasimod may want to know about potential adverse events reported after these drugs entered the market, especially for nervous‑system, eye, and cardiac symptoms.
This paper summarizes post‑marketing reports and highlights unexpected signals that clinicians may monitor for.
Who Should Pay Attention
Clinicians prescribing S1P modulators, patients on or considering ozanimod or etrasimod, pharmacovigilance researchers, and IBD safety researchers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study analyzed FDA adverse event reports to look for safety signals for the S1P modulators ozanimod and etrasimod in ulcerative colitis. It found multiple system‑level signals including nervous system, eye, and cardiac disorders; common reported events included headache, dizziness, nausea, blurred vision, and reports of drug ineffective.
The authors note limitations of spontaneous reporting data and call for prospective validation.
What the paper reports: a disproportionality analysis of post‑marketing adverse event reports (FAERS) for ozanimod (n=1632 reports) and etrasimod (n=283 reports), using reporting odds ratio, proportional reporting ratio, and a Bayesian neural network to identify signals. Median reported onset time was ~17.5 days for both drugs.
How to use this information: the paper provides a broad safety signal scan rather than proven incidence rates; signals flagged here may warrant clinician awareness (for monitoring symptoms such as visual changes, dizziness, or cardiac symptoms) and further study.
Limitations: FAERS is subject to underreporting, reporting bias, and cannot establish causality—these results need confirmation in prospective studies.
Keep In Mind
Findings come from the FDA spontaneous reporting database (FAERS) and indicate associations (safety signals) but do not prove causation or provide incidence rates. The authors recommend prospective studies to validate these signals.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMedicine
PublisherOvid Technologies (Wolters Kluwer Health)
AuthorsLong Chen, Dongping Wan, Benkai Xing +4 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study.
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.
Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...